Debiopharm and NetTargets Partner to Identify Drug Combinations for ADCs
Debiopharm, a Swiss-based company, has formed a research partnership with NetTargets, a South Korea-based AI drug discovery company.
NetTargets utilizes an AI system that combines multi-omics data with neural network modeling for drug discovery.
The partnership aims to identify and develop synergistic drug pairings for Debiopharm's antibody-drug conjugates (ADCs).
The gold standard of business intelligence.
The partnership combines business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Author's summary: Debiopharm partners with NetTargets for ADC drug combos.
More News
- How former Gonzaga stars perform in NBA
- Hamilton urges Ferrari to make 'personnel changes' ahead of F1 2026
- F1 2026 : Lancements, livrées et premiers indices d'une révolution en piste
- Jay Kelly cast guide: All on which characters George Clooney, Adam Sandler and Laura Dern play in the film
- How to watch Islanders vs. Lightning: TV channel and streaming options for December 6
- Kelly Osbourne — Instagram Snapshot
- Lando Norris wins his first F1 title despite Max Verstappen victory: Live updates and reaction
- Lightning vs. Islanders Prediction, Odds, Picks - Dec. 6
- Game Preview: Islanders vs Lightning
- Spurs' Kelly Olynyk: Ongoing Decline in Playing Time and Role